ClinMed Pharma
Market access

Value based health care is gaining traction to
reduce the gap between the rise in demand
for new interventions and the limited
financial resources available.

The critical appraisal of cost-effectiveness by health care payers and their nominated agencies have applied pressure on health care developers to review health economics and outcomes research (HEOR) earlier in their clinical development plans to gain optimal pricing and reimbursement.

At ClinMed Pharma, our team have supported organisations navigate through the UK National Institute of Clinical Excellence (NICE) Health Technology Assessment (HTA). We have also supported pricing and reimbursement research commissioned by the French Ministry of Health and Social Affairs and also modelling for (HEOR) for agencies in the US and Asia.

Related content

Request for information

Learn more

Request for proposal

Learn more